Saturday 17 October 2026
Export CARM’s income statement to Excel — free account
Carisma Therapeutics Inc.
CARM Healthcare Biotechnology
Carisma Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $19.6 million, up 31.6% from fiscal 2023. In the quarter to September 2025, revenue grew 392.0%, EPS grew 445.2% and free cash flow grew 114.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.02
−100.00%
Follow CARM
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | — | 4 |
| 8,783.88% | 394.03% | 216.35% | (134.11%) | ||
| (100.78%) | (113.13%) | (153.46%) | 33.09% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(497.55%) | (1,447.53%) | 1,060.73% | (853.72%) | |
Average Days of Receivables |
0.00 | 0.00 | — | 0.00 | |
Free Cash Flow per Share |
(1.45) | (1.13) | (0.88) | (0.52) | |
Free Cash Flow |
(60.04) | (47.14) | (36.66) | (21.73) | |
Capital Expenditures |
(0.12) | 0.42 | 0.69 | 0.69 | |
| Other line items | |||||
Cash ROIC |
601.60% | 162.99% | 83.30% | (1,137.59%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
303.96% | 257.30% | 0.00% | 48.83% | |
Selling, General and Administrative Expense of Revenue |
112.76% | 103.19% | 0.00% | 25.76% | |
Share Based Compensation of Revenue |
18.59% | 15.53% | 0.00% | 3.95% | |
Operating CF/Net income |
0.99 | 0.94 | 0.76 | (2.79) | |
Depreciation/Fixed assets |
0.76 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.04) | 0.18 | 0.33 | 0.52 | |
Revenue per Share |
0.47 | 0.48 | 0.00 | 1.34 | |
Operating CF per Share |
(1.45) | (1.14) | (0.89) | (0.54) | |
Capex per Share |
0.00 | 0.01 | 0.02 | 0.02 | |
Capex to Sales |
0.01 | (0.02) | 0.00 | (0.01) |
Columns are period end dates